---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-007703"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-01-26T23:59:59+00:00"
generated_at: "2026-06-06T16:34:52.645031+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corbus announces Phase 1 data for CRB-701: 43% ORR at therapeutic doses, no peripheral neuropathy or skin rash

## Summary
- Phase 1 dose-escalation data for CRB-701 (SYS6002) in nectin-4 positive tumors presented at ASCO GU 2024.
- At doses ≥2.7 mg/kg (n=7), ORR 43% (3 partial responses) and disease control rate 71%; no grade 3+ adverse events.
- No dose-limiting toxicities, peripheral neuropathy, or skin rash observed; dose escalation ongoing at 4.5 mg/kg.
- CRB-701 showed lower free MMAE exposure vs enfortumab vedotin; longest ongoing response ~10 months.
- U.S. clinical study expected to start in Q1 2024 under already-open IND.

## SEC filing metadata
- accession: 0000950170-24-007703
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024007703/0000950170-24-007703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024007703/crbp-20240126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-007703
- JSON: https://secwatch.observer/filing/0000950170-24-007703.json
- Plain text: https://secwatch.observer/filing/0000950170-24-007703.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.